Literature DB >> 8301215

Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro.

C S Spada1, A L Nieves, A H Krauss, D F Woodward.   

Abstract

The motility of isolated normal human peripheral blood eosinophils and neutrophils in response to exogenous leukotrienes B4 and D4 was examined by means of a modified under-agarose technique and a novel quantitative sampling strategy. Leukotriene D4 was a potent chemoattractant for eosinophils, with a significant threshold chemotactic effect evident at 10(-10) M. The abolition of eosinophil chemotaxis by the potent and selective peptide-leukotriene-antagonist SK&F 104353 indicated the pharmacological specificity of the leukotriene D4-induced response. The chemokinetic response of eosinophils to leukotriene D4 generally did not differ significantly from spontaneous migratory activity of unstimulated cells. Leukotriene D4 did not, however, alter directed neutrophil motility until a very high concentration (10(-5) M) was achieved, although significant neutrophil chemokinesis relative to unstimulated movement was observed over the tested concentration range. Directional emigration of both eosinophils and neutrophils was induced by leukotriene B4 at concentrations as low as 10(-8) M. Analysis of leukocyte orientations provided evidence that chemokinetic responses were not being interpreted as indications of chemotactic behavior. These studies suggest that leukotriene D4 may behave as a potent and selective chemoattractant for human eosinophils at physiologically relevant concentrations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301215     DOI: 10.1002/jlb.55.2.183

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  26 in total

Review 1.  Antileukotrienes and laboratory models of asthma.

Authors:  S C Lazarus
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Regulation of expression of the 5-lipoxygenase pathway.

Authors:  T D Bigby
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 3.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 4.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

5.  Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors.

Authors:  Neerad C Mishra; Jules Rir-sima-ah; R Thomas Boyd; Shashi P Singh; Sravanthi Gundavarapu; Raymond J Langley; Seddigheh Razani-Boroujerdi; Mohan L Sopori
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

Review 6.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

7.  Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats.

Authors:  M Salmon; D A Walsh; T J Huang; P J Barnes; T B Leonard; D W Hay; K F Chung
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

8.  Biological effects of leukotriene E4 on eosinophils.

Authors:  John W Steinke; Julie Negri; Spencer C Payne; Larry Borish
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-03-26       Impact factor: 4.006

9.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 10.  Leukotriene receptors as potential therapeutic targets.

Authors:  Takehiko Yokomizo; Motonao Nakamura; Takao Shimizu
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.